

Beactica Therapeutics' small molecule platform enables the efficient development of innovative drug candidates

With its powerful and versatile platform, Beactica Therapeutics identifies innovative small molecule drug candidates that have a targeted effect against carefully selected disease proteins. Strategic collaborations provide access to valuable knowledge and opportunities to work with a broader portfolio. We speak to the company's CEO, Dr Per Källblad.



Per Källblad
CEO at Beactica Therapeutics

collaborate with others who are also at the forefront. By establishing research collaborations with leading universities and institutes, both locally and globally, Beactica effectively gains access to valuable expertise and knowledge that would have been extremely expensive to build internally.

-To accelerate our development programs, we also enter into strategic partnerships with other pharmaceutical companies. This enables us to progress our programmes faster so that our innovative compounds can benefit patients more quickly. Beactica currently has two outlicensed programs run by two Korean pharmaceutical companies. They will be responsible for clinical trials and the commercialization of our drug candidates. The partnerships also provide important income that we can invest in broadening our pipeline with additional programmes. In parallel with our partners advancing our outlicensed products, the goal is to have a wholly-owned project in the clinic within three years.

In March 2021, you signed a collaboration agreement with the Korean pharmaceutical company Oscotec. What does this strategic partnership agreement mean for your continued development?

- The license deal with Oscotec is a milestone for Beactica and has a total possible deal value of more than SEK 1.5 billion. Initially, we collaborate on research and preclinical development of new anti-cancer substances from our LSD1 program. Oscotec is then given the right to take full responsibility for clinical development and commercialization. We are proud of this partnership with Oscotec, and their focus on immunology and oncology makes them an ideal partner for this particular program. The collaboration also frees up resources for us to focus more on our previous development projects and thereby broaden our pipeline of innovative products.

What are your main competitive advantages?

- An important competitive advantage is our versatile and validated technology platform, which can be applied widely to provide innovative approaches to extremely difficult disease proteins. Another competitive advantage is our global business and research network, which we have methodically built up over these past 15 years.

Beactica Therapeutics is currently a privately owned company. Can a stock exchange listing be relevant to you eventually?


- Today, the company has about forty shareholders who have financed the company since we initiated work with our internal pipeline six years ago. Discussions with strategic and long-term investors who see Beactica's development potential are always interesting. We are continually reviewing various financing alternatives and may consider a stock exchange listing in the future.

Tell us about Beactica Therapeutics and your business concept

-We are a research company founded on world-leading expertise in molecular interactions and drug design. We have a technology platform that enables the efficient identification of innovative small molecules that can be widely applied. The platform has been validated over fifteen years in collaboration with several global pharmaceutical companies such as Janssen, Takeda, Boehringer Ingelheim and Sanofi. We are now using it to build our own pipeline of products for outlicensing. Our primary focus is cancer, an area where there is a huge need for better medicines. Cancer is also the disease area where most licensing deals are made, which can be a very attractive alternative to conducting your own development in the more advanced clinical stages.

Strategic partnerships with research institutes, universities and pharmaceutical companies are a central part of your business strategy. In what way are partnerships important for the company's continued development?

-New knowledge about diseases is developing very fast today, as shown during the current pandemic. In order to maintain a leading position in our competitive industry, it is extremely important to be out in the field and



Facts: Beactica Therapeutics AB is a specialist drug discovery company, utilising its proprietary methodologies to evaluate the interactions of molecules in order to generate novel therapeutics. As well as advancing its own pipeline of first-in-class small molecule allosteric modulators of disease-associated proteins, with a focus in oncology, Beactica offers partnerships using its proprietary drug discovery platform. Founded in 2006 based on research carried out at Uppsala University, Beactica has established a reputation as a world-leader in fragment-based drug discovery using SPR biosensor technology.